Evalaroza, Rosevil .
HRN: 21-88-52 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/09/2022
CEFUROXIME 1.5GM (VIAL)
09/09/2022
09/16/2022
IV
1.5 G
Q8H
Soft Tissue Injuries
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes